Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 138

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 138
---
 some key opinion leaders in the Lyme community have postulated, using the veterinary literature as an analog, that life-long infection by sequestering forms of Babesia(e.g., B. odocoilei) may be a significant driver of chronic fatigue symptoms. 48If this is true, the addressable market for antibabesial drugs may be substantially larger than stated above, since the prevalence of chronic fatigue syndrome in the U.S. is at least 3.3 million cases (excluding Long COVID and PTLDS). 49

| 42 | See https://www.cdc.gov/lyme/signs-symptoms/chronic-symptoms-and-lyme-disease.html.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 43 | Conclusions from Company-commissioned market research.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 44 | Conclusions from Company-commissioned market research.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 45 | Maximum prevalence determined by multiplying the rate of Babesia coinfection in PTLDS patients (52%, from Parveen & Bhanot, Pathogens 2019;8(3):117) by the highest estimate of the cumulative prevalence of PTLDS (1,994,189, from Delong et al. BMC Public Health 2019;19(1):352). Maximum new cases determined by multiplying the number of new Lyme cases per year (476,000, from Krugeler et al (Emerg Infect Dis 2021;27:616-61) by the number of new cases that subsequently become chronic cases (up to 10%, from Delong et al. BMC Public Health 2019;19(1):352) by the proportion of such patients coinfected with Babesia (52%, from Parveen & Bhanot, Pathogens 2019;8(3):117). |
| 46 | See https://www.cdc.gov/lyme/signs-symptoms/chronic-symptoms-and-lyme-disease.html.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 47 | Walitt et al Nature Communications 2024;15:907.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 48 | Lindner HH. 2022. Chronic babesiosis caused by B. odocoilei: Diagnosis, pathophysiology & treatment. Presentation at the 2022 ILADS scientific meeting, Orlando Florida.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 49 |